Nanobiotix S.A./€NANO
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Nanobiotix S.A.
Nanobiotix S.A. is a biotechnology company focusing on developing innovative nanomedicine solutions for cancer therapy. Its core business is centered around the development of NBTXR3, a radioenhancer designed to increase the efficacy of radiotherapy in cancer treatment. Founded in 2003, Nanobiotix is headquartered in Paris, France. Its strategic positioning lies in its proprietary nanotechnology platform, which aims to address unmet needs in oncology by potentially improving outcomes and safety for patients undergoing radiotherapy. The company operates primarily within the European and U.S. markets, with ongoing clinical trials to expand its therapeutic applications.
Ticker
€NANO
Sector
Primary listing
PAR
Employees
103
Headquarters
Website
Nanobiotix S.A. Metrics
BasicAdvanced
€777M
-
-€1.09
1.64
-
Price and volume
Market cap
€777M
Beta
1.64
52-week high
€25.50
52-week low
€2.62
Average daily volume
9K
Financial strength
Current ratio
0.633
Quick ratio
0.582
Long term debt to equity
-67.445
Total debt to equity
-74.313
Interest coverage (TTM)
-5.19%
Profitability
EBITDA (TTM)
-43.844
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-508.35%
Operating margin (TTM)
-432.39%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
€100,000
Management effectiveness
Return on assets (TTM)
-41.64%
Return on equity (TTM)
113.84%
Valuation
Price to revenue (TTM)
77.939
Price to book
-11.27
Price to tangible book (TTM)
-11.27
Price to free cash flow (TTM)
-25.024
Free cash flow yield (TTM)
-4.00%
Free cash flow per share (TTM)
-0.667
Growth
Revenue change (TTM)
-75.93%
Earnings per share change (TTM)
39.60%
3-year revenue growth (CAGR)
56.37%
10-year revenue growth (CAGR)
11.46%
3-year earnings per share growth (CAGR)
-4.05%
10-year earnings per share growth (CAGR)
1.76%
Bulls say / Bears say
Nanobiotix successfully dosed the first patient in the Johnson & Johnson–sponsored CONVERGE randomized Phase II trial for Stage 3 unresectable non-small cell lung cancer, demonstrating progress in expanding NBTXR3’s therapeutic pipeline beyond pancreatic and head and neck cancers. (BioSpace)
The March 2025 amendment to the global licensing agreement with Janssen Pharmaceutica allocates nearly all cost responsibilities for the pivotal NANORAY-312 Phase III head and neck cancer trial to J&J, extending Nanobiotix’s cash visibility to mid-2026 and materially lowering its R&D burn rate. (The Pharma Letter)
European health authorities formally reclassified NBTXR3 from a medical device to a medicinal product in July 2025, harmonizing its regulatory status with the US and simplifying future global filings under unified drug regulations. (The Pharma Letter)
As of June 30, 2025, Nanobiotix held only €28.8 million in cash and equivalents, projecting operational runway into mid-2026 and warning that existing funds are insufficient to cover the next 12 months without additional financing. (Nanobiotix IR)
The apparent reduction in net loss to €5.4 million in H1 2025 was driven primarily by a €21.2 million non-cash revenue recognition from the J&J licensing amendment, potentially obscuring underlying operational performance. (Nanobiotix IR)
The licensing amendment also released Johnson & Johnson from select future milestone payments, capping Nanobiotix’s potential upside and introducing uncertainty around the realization of anticipated milestone revenues. (The Pharma Letter)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nanobiotix S.A. stock?
Nanobiotix S.A. (NANO) has a market cap of €777M as of October 27, 2025.
What is the P/E ratio for Nanobiotix S.A. stock?
The price to earnings (P/E) ratio for Nanobiotix S.A. (NANO) stock is 0 as of October 27, 2025.
Does Nanobiotix S.A. stock pay dividends?
No, Nanobiotix S.A. (NANO) stock does not pay dividends to its shareholders as of October 27, 2025.
When is the next Nanobiotix S.A. dividend payment date?
Nanobiotix S.A. (NANO) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix S.A.?
Nanobiotix S.A. (NANO) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.